ATNFW实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (29 Jun 2024 @ 04:00):
Our systems believe the stock currently is undervalued by 0.37% compare to its pairs and should correct upwards.

Stats
今日成交量	77 054
平均成交量	0
市值	1.43M
EPS	$-1.680 ( Q1 \| 2024-05-15 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0 (Sector) 42.63 (Industry) 0
ATR14	$0.00100 (9.80%)

ATNFW 10.87%

HROWL 0.35%

HROWM -0.19%

LFLYW -17.03%

Insider Trading

Date	Person	Action	Amount	type
2023-12-28	Feldmann Marc	Buy	135 377	Common Stock
2023-12-15	Feldmann Marc	Sell	25 000	Common Stock
2023-12-15	Woody James N.	Buy	25 000	Common Stock
2023-09-04	Feldmann Marc	Buy	15 000	Non-Qualified Stock Option (right to buy)
2023-09-04	Ray Russell T	Buy	21 455	Common Stock

INSIDER POWER
91.30
Last 31 transactions
Buy: 766 364 \| Sell: 25 000

相关性 (AI algo v.1.1b): Undervalued: 0.37% $0.0102 paired level. (算法实时跟踪最相关股票的变化并提供即时更新)

CannBioRx Life Sciences 相关性

10 最正相关
JDZG	0.851
BWIN	0.812

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

CannBioRx Life Sciences 财务报表

Annual	2023
营收:	$0
毛利润:	$-105 675 (0.00 %)
EPS:	$-52.60

FY	2023
营收:	$0
毛利润:	$-105 675 (0.00 %)
EPS:	$-52.60

FY	2022
营收:	$0
毛利润:	$-109 004 (0.00 %)
EPS:	$-387.19

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$0

Financial Reports:

No articles found.

CannBioRx Life Sciences Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

CannBioRx Life Sciences

180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard on September 7, 2016 and is headquartered in Palo Alto, CA.